SCHEMBL29323850

SCHEMBL29323850

Cc1cnc(C[S+]([O-])c2nc3ccccc3[nH]2)c(C)c1OCC(C)(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SARM1 Q6SZW1 2/20 0.53
KMT2A Q03164 6/20 0.43
WDR5 P61964 5/20 0.43
NPC1 O15118 6/20 0.36
RAB9A P51151 6/20 0.36
CYP2C9 P11712 4/20 0.36
CYP1A2 P05177 3/20 0.36
CYP3A4 P08684 3/20 0.36
CYP2C19 P33261 3/20 0.36
CYP2D6 P10635 2/20 0.36
ENGASE Q8NFI3 3/20 0.35
ATP1A1 P05023 3/20 0.35
ATP1B1 P05026 3/20 0.35
ATP1A3 P13637 3/20 0.35
ATP1B2 P14415 3/20 0.35
ATP4A P20648 3/20 0.35
ATP1A2 P50993 3/20 0.35
ATP4B P51164 3/20 0.35
ATP1B3 P54709 3/20 0.35
FXYD2 P54710 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21945694 0.93 SARM1 (0.61) SARM1KMT2AWDR5NPC1RAB9A
SCHEMBL23988439 0.93 SARM1 (0.61) SARM1KMT2AWDR5NPC1RAB9A
SCHEMBL6440042 0.93 SARM1 (0.61) SARM1KMT2AWDR5NPC1RAB9A
SCHEMBL6877030 0.91 SARM1 (0.52) SARM1KMT2AWDR5NPC1RAB9A
SCHEMBL23988508 0.87 KMT2A (0.47) SARM1KMT2AWDR5NPC1RAB9A
SCHEMBL5348112 0.86 WDR5 (0.58) SARM1KMT2AWDR5NPC1RAB9A
SCHEMBL23988442 0.86 WDR5 (0.58) SARM1KMT2AWDR5NPC1RAB9A
SCHEMBL5348110 0.86 WDR5 (0.58) SARM1KMT2AWDR5NPC1RAB9A
SCHEMBL8119116 0.84 KMT2A (0.45) SARM1KMT2AWDR5NPC1RAB9A
SCHEMBL14175413 0.83 NPC1 (0.54) SARM1KMT2AWDR5NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238264-A1 INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF DISARM THERAPEUTICS, INC. 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238264-A1 INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF SARM1, NADK, NNMT SARM1 1/4885KMT2A 2098/4885WDR5 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.